|
Volumn 223, Issue 5, 2011, Pages 565-566
|
Unveiling the molecular pathogenesis of chordoma: A new paradigm for molecular targeting of rare cancers
|
Author keywords
Chordoma; EGFR; Rare cancer; T; Target therapy
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
IMATINIB;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
MITOGEN ACTIVATED PROTEIN KINASE;
PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;
PROTEIN KINASE B INHIBITOR;
RAS PROTEIN;
TYRPHOSTIN;
BAYES THEOREM;
CANCER PATIENT;
CHORDOMA;
CLINICAL TRIAL (TOPIC);
DRUG EFFICACY;
DRUG INHIBITION;
EVIDENCE BASED PRACTICE;
GENE DUPLICATION;
GENE EXPRESSION;
GENE MUTATION;
HUMAN;
MOLECULAR GENETICS;
MOLECULARLY TARGETED THERAPY;
NOTE;
PATHOGENESIS;
PRIORITY JOURNAL;
PROBABILITY;
PROTEIN PHOSPHORYLATION;
RARE DISEASE;
SIGNAL TRANSDUCTION;
TUMOR CELL LINE;
ANTINEOPLASTIC AGENTS;
CHORDOMA;
GENES, ERBB-1;
GENETIC PREDISPOSITION TO DISEASE;
HUMANS;
MOLECULAR TARGETED THERAPY;
RARE DISEASES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
EID: 79952570454
PISSN: 00223417
EISSN: 10969896
Source Type: Journal
DOI: 10.1002/path.2847 Document Type: Note |
Times cited : (11)
|
References (11)
|